Clene reports significant survival benefit with CNM-Au8 in ALS compassionate use programs

Clene Inc.

68% decreased risk of all-cause mortality vs PRO-ACT matched controls (HR=0.320, p=0.0001).
57% decreased risk of all-cause mortality vs ALS Natural History Consortium matched controls (HR=0.433, p=0.0001).
Data from 256 EAP participants (220 matched); no serious adverse events attributed to CNM-Au8.
Results support advancing CNM-Au8 to Phase 3 testing in ALS; $45.1M NIH grant for third EAP.
CNM-Au8 30 mg well-tolerated with up to 4 years of dosing; EAP enrollment in H1 2024 planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.